PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail aims to help ITP patients ditch Long-Term meds
Disease control Not yet recruitingThis study tests whether combining two drugs—orelabrutinib and romiplostim—can improve platelet counts and allow patients with chronic immune thrombocytopenia (ITP) to stop treatment. About 28 adults who haven't responded well to standard therapy will take the combo for 24 weeks.…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
New drug sequence aims to boost platelets in severe ITP
Disease control Not yet recruitingThis study tests a treatment plan for adults with severe immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. Participants will receive a 14-day hospital treatment of high-dose steroids plus a platelet-boosting drug, follow…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE4 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated May 26, 2026 05:46 UTC
-
New hope for ITP patients: study tests drug switch after first treatment fails
Disease control Not yet recruitingThis study looks at 112 people with immune thrombocytopenia (ITP) whose platelet counts didn't improve after standard treatment with rhTPO. After a two-week break, half will get a higher dose of rhTPO and half will switch to a different drug called eltrombopag. The goal is to see…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 20, 2026 11:56 UTC